Aclarion, Inc. (NASDAQ:ACON – Get Free Report) CEO Brent Ness acquired 6,289 shares of the stock in a transaction on Monday, May 11th. The stock was bought at an average price of $3.18 per share, for a total transaction of $19,999.02. Following the transaction, the chief executive officer owned 6,300 shares in the company, valued at approximately $20,034. This represents a 57,172.73% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.
Aclarion Trading Up 4.1%
Aclarion stock opened at $3.28 on Thursday. Aclarion, Inc. has a 12 month low of $2.34 and a 12 month high of $12.03. The stock’s 50 day simple moving average is $3.29 and its two-hundred day simple moving average is $4.46. The firm has a market cap of $8.07 million, a PE ratio of -0.19 and a beta of 1.18.
Aclarion (NASDAQ:ACON – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.55) by $0.21. Aclarion had a negative return on equity of 52.31% and a negative net margin of 9,517.11%. On average, equities research analysts forecast that Aclarion, Inc. will post -4.37 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on ACON shares. Weiss Ratings lowered Aclarion from a “sell (e+)” rating to a “sell (e)” rating in a research report on Friday, May 8th. Wall Street Zen upgraded Aclarion from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Aclarion currently has a consensus rating of “Sell”.
Get Our Latest Research Report on ACON
About Aclarion
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.
Further Reading
- Five stocks we like better than Aclarion
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
